Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this ...

A small study of Novo Nordisk's once-daily injectable GLP-1 agonist liraglutide shows a benefit in patients with Alzheimer's disease.

Semaglutide is marketed under the brand names, such as Ozempic, which is primarily prescribed for those with Type 2 diabetes, and Wegovy, which is commonly prescribed for weight loss. The drug mimics ...

The exact numbers depended on the type of medication patients took, but the risk of developing Alzheimer’s was up to 70 ...

Animal studies support that theory. GLP-1 drugs reduce inflammation in the brain and interfere with reward pathways linked to ...

Previous studies have concluded that early intervention in dementia cases can increase patients' treatment options and ...

Novo Nordisk's pipeline, especially the oral GLP-1 and Alzheimer’s trial, offers significant long-term upside. Click here to ...

The longer weight loss GLP-1 drugs like Ozempic and Wegovy have been on the market, the more side effects people are reporting. In very rare cases they can be deadly. Here’s what to know.

The longer weight loss GLP-1 drugs like Ozempic and Wegovy have been on the market, the more side effects people are ...

An updated edition of the June 4, 2025 article. The world is in the midst of a historic demographic shift with populations ...

Dr Rowan French insists lasting weight loss can only be achieved through a balanced approach to psychology, exercise and ...